When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRVB - Provention Bio initiates Phase 2b PROACTIVE study of PRV-015
Provention Bio Inc.
Provention Bio (PRVB+1.1%) announced the initiation of the Phase 2b PROACTIVE study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as 'Non-Responsive Celiac Disease'.
More news on: Provention Bio, Inc., Healthcare stocks news,